Good morning and welcome to Bausch + Lomb’s Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event ...

One Bloomberg estimate projected the sale to value Bausch + Lomb at over $13 billion, making the deal potentially one of the ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

Bausch + Lomb Corporation ( (BLCO) ) has realeased its Q3 earnings. Here is a breakdown of the information Bausch + Lomb Corporation presented ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

Bausch Health shares rose Thursday morning after the company raised its full year outlook following a better-than-expected third-quarter performance. Shares traded over 11% higher in Toronto at 12.68 ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results.

This growth has been attributed to strategic product launches such as the enVista NV intraocular lens, Blink NutriTears, and Bausch + Lomb INFUSE contact lenses. As a result, the company has raised ...

Private equity groups TPG and Blackstone have teamed up to work on a joint bid for eyecare company Bausch + Lomb, according to people familiar with the matter. If it goes through, the deal could be ...

Bausch + Lomb will host a conference call and live ... Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic ...